Jazz Pharmaceuticals (NASDAQ:JAZZ) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) in a report released on Monday, Benzinga reports. The brokerage currently has a $204.00 price target on the specialty pharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. Needham & Company LLC dropped their price objective on shares of Jazz Pharmaceuticals from $210.00 to $205.00 and set a buy rating on the stock in a research report on Thursday, March 2nd. The Goldman Sachs Group lifted their price target on shares of Jazz Pharmaceuticals from $190.00 to $212.00 and gave the stock a buy rating in a research note on Friday. StockNews.com downgraded shares of Jazz Pharmaceuticals from a strong-buy rating to a buy rating in a report on Monday, February 27th. Finally, Royal Bank of Canada boosted their price objective on Jazz Pharmaceuticals from $206.00 to $207.00 and gave the stock an outperform rating in a report on Thursday, November 10th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of Moderate Buy and an average price target of $204.27.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $142.78 on Monday. Jazz Pharmaceuticals has a twelve month low of $125.36 and a twelve month high of $169.98. The company has a 50 day moving average of $152.49 and a two-hundred day moving average of $148.58. The company has a quick ratio of 2.03, a current ratio of 2.79 and a debt-to-equity ratio of 1.85. The company has a market cap of $9.04 billion, a price-to-earnings ratio of -40.22, a price-to-earnings-growth ratio of 0.76 and a beta of 0.73.

Insider Buying and Selling

In related news, EVP Robert Iannone sold 1,844 shares of the firm’s stock in a transaction that occurred on Friday, December 9th. The shares were sold at an average price of $151.54, for a total value of $279,439.76. Following the sale, the executive vice president now owns 36,316 shares in the company, valued at $5,503,326.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Jazz Pharmaceuticals news, EVP Robert Iannone sold 1,844 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, December 9th. The stock was sold at an average price of $151.54, for a total value of $279,439.76. Following the sale, the executive vice president now owns 36,316 shares of the company’s stock, valued at approximately $5,503,326.64. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 3,000 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $159.86, for a total value of $479,580.00. Following the completion of the sale, the chief executive officer now owns 368,078 shares in the company, valued at $58,840,949.08. The disclosure for this sale can be found here. Insiders sold a total of 9,541 shares of company stock worth $1,503,696 in the last three months. 4.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Fifth Third Bancorp raised its position in Jazz Pharmaceuticals by 32.9% in the second quarter. Fifth Third Bancorp now owns 279 shares of the specialty pharmaceutical company’s stock valued at $44,000 after purchasing an additional 69 shares during the period. Park Avenue Securities LLC boosted its position in shares of Jazz Pharmaceuticals by 2.3% in the 4th quarter. Park Avenue Securities LLC now owns 3,100 shares of the specialty pharmaceutical company’s stock valued at $494,000 after purchasing an additional 70 shares during the period. IFP Advisors Inc raised its stake in Jazz Pharmaceuticals by 26.5% during the 4th quarter. IFP Advisors Inc now owns 358 shares of the specialty pharmaceutical company’s stock valued at $64,000 after acquiring an additional 75 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of Jazz Pharmaceuticals by 2.4% during the 1st quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock worth $577,000 after buying an additional 86 shares in the last quarter. Finally, First Republic Investment Management Inc. increased its position in shares of Jazz Pharmaceuticals by 0.7% in the fourth quarter. First Republic Investment Management Inc. now owns 12,062 shares of the specialty pharmaceutical company’s stock valued at $1,922,000 after buying an additional 88 shares in the last quarter. 89.79% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

(Get Rating)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.